The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predicting Radiotherapy Response and Toxicities in Soft Tissue Sarcoma of the Extremities - Cohort B (PredicT-B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05978024
Recruitment Status : Recruiting
First Posted : August 7, 2023
Last Update Posted : August 7, 2023
Sponsor:
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is a multicentre prospective cohort study, primarily aimed at reporting the frequency and intensity of radiotherapy side-effects of patients with soft tissues sarcoma of the extremities (STSE).

Two sub-studies are proposed within this study:

  • MRI radiation response assessment Aimed at establishing whether changes in median apparent diffusion coefficients (ADC) are predictive of pre-operative STSE response measured using histopathology.
  • Biomarker development and Immune mediators associated with radiotherapy Aimed at establishing prognostic markers which may refine selection of cases for pre-operative, palliative or no radiotherapy.

Also, aimed at determining if radiotherapy stimulates the tumour microenvironment, resulting in measurable change in anti-tumour immunity and if certain subtypes could potentially benefit from the addition of immunotherapy with radiation.

Patients participation in the sub-studies is optional.


Condition or disease
Soft Tissue Sarcoma of the Extremities

Detailed Description:

This is a multicentre prospective cohort study, primarily aimed at validating the dose-volume parameters identified in the analyses of the VorteX and IMRiS trials datasets.

• Delineation of healthy tissues

Pre-defined outlining guidelines of normal tissues as bones, muscle compartments, joints, lymph drainage basins and subcutaneous tissue from Predict A will be delineated in radiotherapy planning computed tomography (CT) images. All cases will be delineated by a single observer (Rita Simoes). Verification of all outlines will be carried out by Dr Aisha Miah (clinical supervisor).

• Dose-volume constraints validity testing

Patients will be treated as per local protocol treatment technique.

Radiotherapy, clinical and toxicities data will be collected, with no new intervention on the treatment. Patients enrolled will receive standard radiation prescription doses as described below:

  • Pre-operative radiotherapy- 50 Gy in 25 fractions equivalent (pre-operative radiotherapy). Where appropriate hypo-fractionated schedules as per institutional guidelines can considered: eg. 25 Gy/ 5 daily fractions. In myxoid liposarcomas, 36 Gy in 18 fractions can be considered where suitable;
  • Post-operative radiotherapy- 60 Gy in 30 fractions or 66 Gy in 33 fractions (positive resection margins); alternative hypo-fractionated schedules as per institutional guidelines can be considered;
  • Palliative radiotherapy- 30-36 Gy in 10-12 daily fractions, 40-45 Gy in 15 fractions, 30-36 Gy in 5-6 once weekly fractions or 25 Gy in 5 daily fractions.

Toxicity will be assessed with the TESS and RTOG scoring instruments and Stern score for lymphoedema. Patients enrolled in the study will fill in a specific quality-of-life questionnaire to assess quality of life related functional outcomes following treatment for STSE. This questionnaire is based on validated questions for assessing quality-of-life. Patients will be followed up at 3, 6, 12, 18, and 24 months post-radiotherapy.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predicting Radiotherapy Response, Toxicities and Quality of Life Related Functional Outcome in Soft Tissue Sarcoma of the Extremities: a Prospective Observational Cohort Study
Actual Study Start Date : April 16, 2021
Estimated Primary Completion Date : July 30, 2024
Estimated Study Completion Date : July 30, 2026

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The incidence of any RTOG grade ≥ 2 toxicities following treatment for STSE at 24 months [ Time Frame: 24 Months ]
    The primary objective is to report the frequency and intensity of radiotherapy side-effects in STSE.


Secondary Outcome Measures :
  1. The ability of the fitted model from dose-volume constraints from PredicT A (IMRiS and Vortex analysis) to correctly predict the incidence of grade 2+ among PredicT B patients. [ Time Frame: 24 Months ]
    To report the differences in experienced by patients with STSE for whom dose-volume constraints were below or exceeded. Binary logistic regression will be used to quantify the differences using odds ratios (OR) from the fitted models. Univariate logistic regression models will be fitted to predict for the parameters relevant to toxicity grades in the RTOG, Stern's and TESS scales. ORs for each of the parameters will be used to judge for significant differences between the groups. There is no plan to fit multivariate model.

  2. To report frequencies and proportions of radiotherapy-induced late toxicities [ Time Frame: 24 Months ]

    Frequencies and proportions of radiotherapy-induced late toxicities at the specified at 3, 6, 12, 18 and 24 months will be reported descriptively at each time point for the overall events and by types of events:

    1. Subcutaneous tissue fibrosis
    2. Lymphoedema
    3. Bone fractures
    4. Joint stiffness
    5. Delayed wound healing following pre-operative RT

  3. To determine the time to developing early and late side-effects. [ Time Frame: 24 Months ]
    Time elapsed between day 1 of radiotherapy and the day to develop early and late side-effects using Kaplan-Meier methods. Median time to early side-effects with 95% confidence interval will be reported. Patients without any side-effects (on day 90 from end of RT) will be censored. Similarly, median time to late side-effects with 95% confidence interval will be reported. Patients without an event will be censored at the 24 months assessment visit or at last follow-up date known to be on the study without any event.

  4. To determine radiological response rates to radiotherapy and where applicable chemo-radiotherapy for STSE of different histological subtypes. [ Time Frame: 24 Months ]
    Differences in the tumour volumes (in cc and %) will be calculated from CT and CBCT images at fractions 8, 16 and 25 for patients receiving pre-operative RT. Changes in target volumes during radiotherapy will be assessed by computing dissimilarity indices (e.g., Simpson's dissimilarity index) in sequential CBCT images captured during treatment compared to radiotherapy planning CT. Radiological: % volume change (RECIST), % cystic sold component).

  5. To determine histological response rates to radiotherapy and where applicable chemo-radiotherapy for STSE of different histological subtypes. [ Time Frame: 24 Months ]
    Differences in the response rates will be assessed according to: histopathological semi-quantitative scores (pathological: % viable cells). Tumour factors are tumour histotype, staging and tumour size.

  6. To determine quality of life-related functional outcomes and explore correlations with dose-volume parameters for patients who have received pre, post-operative or palliative radiotherapy for STSE. [ Time Frame: 24 Months ]
    Correlations between functional outcomes (expressed in TESS and EORT-QLQ- C30 and QLQ-FA12 fatigue questionnaire scores) with dose-volume parameters (expressed in Gy/volume, where volume will be defined in % of total volume and cc) will be calculated using Spearman's correlation method. Patients will be categorised according to dose volume constraints and compare the groups using t-test or Mann-Whitney non-parametric test as appropriate.

  7. To determine predictive and prognostic factors for local and distant recurrence and overall survival for patients receiving pre-operative and palliative RT. [ Time Frame: 24 Months ]
    Percentage of patients responding to treatment will be calculated, this will be reported in the overall patients and for dose-volume constraints groups. Local control rates, disease-free survival rates and overall survival at 2 years will be calculated using Kaplan-Meier methods. Disease free survival events are local or distance disease recurrence and death from disease related causes. Overall survival events are death from any causes.


Biospecimen Retention:   Samples With DNA
  • Tumour tissue for histopathological markers, immune function and DNA damage response from the area receiving radiotherapy (both biopsies and surgical resection specimens)
  • Blood samples for immune function analysis (Up to 50 ml at each time point).

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The study population to be enrolled in this observational study will have had been diagnosed with STSE and referred to receive a course of radiotherapy either in the primary, palliative, pre-operative or post-operative settings.
Criteria

Inclusion Criteria:

  • Histopathological diagnosis of soft tissue sarcoma of the upper or lower limb or limb girdle;
  • Patients receiving pre-operative (neo-adjuvant), post-operative (adjuvant) or palliative radiotherapy;
  • Patients receiving radiotherapy planned as per local protocols (neoadjuvant chemotherapy will be allowed). Neoadjuvant chemotherapy patients may be approached as they commence chemotherapy;
  • WHO performance status 0-2;
  • Aged ≥16 years;
  • Patients fit enough to undergo radiotherapy treatment and willing to attend follow up visits, during two years;
  • Female patients of child-bearing potential and male patients with partners of child-bearing potential must agree to use adequate contraception methods, which must be continued for 3 months after completion of treatment;
  • Capable of giving written informed consent.

Exclusion Criteria:

  • Previous radiotherapy to the same site;
  • Pregnancy;
  • Patients with concurrent or previous malignancy that could compromise assessment of primary and secondary endpoints of the trial.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05978024


Contacts
Layout table for location contacts
Contact: Thuy-Giang Nguyen 02078118090 Thuy-Giang.Nguyen@rmh.nhs.uk
Contact: Stephanie Elston 02078118395 stephanie.elston@rmh.nhs.uk

Locations
Layout table for location information
United Kingdom
Addenbrooke's Hospital Recruiting
Cambridge, United Kingdom, CB2 0QQ
Contact: Katy Cooper         
Principal Investigator: Sarah Prewett         
The Royal Marsden NHS Foundation Trust Recruiting
London, United Kingdom, SW3 6JJ
Contact: Thuy-Giang Nguyen    +442078118090    Thuy-Giang.Nguyen@rmh.nhs.uk   
Principal Investigator: Aisha Miah         
University College London Recruiting
London, United Kingdom, WC1E 6BT
Contact: Carla Dalton         
Principal Investigator: Mahbubl Ahmed         
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Investigators
Layout table for investigator information
Principal Investigator: Aisha Miah The Royal Marsden Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT05978024    
Other Study ID Numbers: CCR5166
First Posted: August 7, 2023    Key Record Dates
Last Update Posted: August 7, 2023
Last Verified: July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description:

Patient outcomes data will be utilised to publish study endpoints. However specific participant data will not be shared.

We aim to publish protocol, and study results in the form of peer-reviewed publications and guidelines

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms